Water-Soluble CC-1065 Conjugates for Tumor Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CC-1065 derivatives lack sufficient selectivity for tumor cells, leading to severe side effects due to non-specific cytotoxicity and poor pharmacological properties such as poor water solubility and aggregation tendencies, and they also face challenges with drug resistance development.
Innovation Solution
Development of novel CC-1065 analogs and conjugates with enhanced cytotoxicity quotients and improved pharmacological properties, including increased water solubility and controlled release mechanisms, to selectively target tumor cells through conjugation with targeting moieties and enzymes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CC-1065 derivatives are used to treat tumors, then cytotoxic activity is achieved, but selectivity for tumor cells is insufficient leading to severe side effects
Solution Approach 1:
The patent employs targeting moieties (such as antibodies, peptides, or ligands) as intermediaries that specifically bind to tumor-associated antigens or receptors. This mediator approach enables selective delivery of the CC-1065 derivative to tumor cells while sparing normal cells, thereby improving selectivity and reducing non-specific cytotoxicity and side effects.
Solution Approach 2:
The patent creates conjugates where the CC-1065 derivative is locally attached to targeting moieties that recognize specific tumor markers. This local quality approach ensures that the cytotoxic agent is concentrated at the tumor site through specific binding, achieving high local efficacy while minimizing systemic exposure and side effects.
2Reliability
If CC-1065 derivatives are administered, then antitumor activity is achieved, but water solubility is poor leading to aggregation tendencies
Solution Approach 1:
The patent creates composite conjugate structures combining the hydrophobic CC-1065 derivative with hydrophilic components such as carbohydrates (e.g., galactose, mannose), peptides, or polymeric carriers. This composite approach maintains the antitumor activity of the core derivative while the hydrophilic components improve water solubility and prevent aggregation, enabling stable formulation and delivery.
Solution Approach 2:
The patent modifies physical-chemical parameters of the CC-1065 derivative by introducing water-soluble groups or conjugating with hydrophilic moieties. This parameter change approach transforms the hydrophobic character of the parent compound into a water-soluble derivative, improving solubility and reducing aggregation while preserving the essential DNA-alkylating activity.
3Reliability
If high doses of CC-1065 derivatives are used to kill all tumor cells, then drug resistance development is reduced, but side effects and toxicity increase
Solution Approach 1:
The patent uses targeting moieties as intermediaries to deliver the cytotoxic agent selectively to tumor cells. This enables the administration of sufficient doses to achieve complete tumor cell killing while the selective targeting mechanism protects normal cells from toxicity, thereby reducing side effects even at effective therapeutic doses.
Solution Approach 2:
The patent employs self-targeting mechanisms where the conjugate inherently directs itself to tumor cells through specific binding interactions between the targeting moiety and tumor-associated markers. This self-service approach ensures that the full therapeutic dose reaches the intended target without requiring external guidance, maximizing tumor cell killing while minimizing off-target toxicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel CC-1065 analogs and conjugates exhibit high cytotoxicity quotients, improved water solubility, and enhanced selectivity for tumor cells, reducing side effects and potential for controlled release, thereby effectively targeting and treating tumors while minimizing drug resistance.
Implementation Method 1
These extremely potent agents allegedly derive their biological activity from an ability to sequence-selectively alkylate DNA at the N3 of adenine in the minor groove
Implementation Method 2
which initiates a cascade of events that terminates in an apoptotic cell death mechanism
Implementation Method 3
the conjugates are designed to release their (multiple) payload after one or more activation steps and/or at a rate and time span controlled by the conjugate
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
This invention relates to novel analogs of the DNA-binding alkylating agent CC-1065 and to their conjugates. Furthermore this invention concerns intermediates for the preparation of said agents and their conjugates. The conjugates are designed to release their (multiple) payload after one or more activation steps and/or at a rate and time span controlled by the conjugate in order to selectively deliver and/or controllably release one or more of said DNA alkylating agents. The agents, conjugates, and intermediates can be used to treat an illness that is characterized by undesired (cell) proliferation. As an example, the agents and the conjugates of this invention may be used to treat a tumor.